NCT03287076View on ClinicalTrials.gov

Trial of EXenatide in Acute Ischaemic Stroke

PHASE2UnknownINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

October 4, 2021

Study Completion Date

December 31, 2021

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Exenatide Injection

5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset

Trial Locations (15)

2010

St Vincent's Hospital Sydney, Darlinghurst

2170

Liverpool Hospital, Liverpool

3004

Alfred Hospital, Melbourne

3050

Royal Melbourne Hospital, Parkville

3065

St Vincent's Hospital Melbourne, Fitzroy

3084

Austin Hospital, Heidelberg

3128

Box Hill Hospital, Box Hill

4029

Royal Brisbane and Women's Hospital, Herston

4102

Princess Alexandra Hospital, Woolloongabba

4575

Sunshine Coast University Hospital, Birtinya

6056

St John of God Midland Public & Private Hospital, Midland

6150

Fiona Stanley Hospital, Murdoch

7250

Launceston General Hospital, Launceston

8140

CDHB Christchurch Hospital, Christchurch

00290

Helsinki University Hospital, Helsinki

Sponsors
All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Monash University

OTHER

lead

Neuroscience Trials Australia

OTHER

NCT03287076 - Trial of EXenatide in Acute Ischaemic Stroke | Biotech Hunter | Biotech Hunter